Ropeginterferon Alfa-2B
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ropeginterferon Alfa-2b: From Polycythemia Vera to Laubry-Pezzi Syndrome
One-Sentence Summary
Ropeginterferon alfa-2b is a long-acting (monopegylated) interferon originally used to treat polycythemia vera, a chronic myeloproliferative neoplasm. The TxGNN model predicts it may be effective for Laubry-Pezzi syndrome (ventricular septal defect with aortic regurgitation), but no clinical trials and no publications currently support this prediction. It is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acquired polycythemia vera (also listed: plasmacytoma, polycythemia) |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (the single BLA is listed as cancelled) |
| Number of NDAs | 1 (BLA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ropeginterferon alfa-2b is a long-acting interferon that modulates JAK2-mutant myeloproliferative clones, and its efficacy in polycythemia vera has been studied in randomized trials.
However, no plausible mechanistic link to the predicted indication can be identified. Laubry-Pezzi syndrome is a structural cardiac anomaly, and interferon-based immunomodulation or antiproliferative activity has no known action on it. The high TxGNN score most likely reflects graph-neighborhood patterns rather than biology, so the prediction should be treated as a hypothesis with no biological support.
Nine other predicted indications were also reviewed, including interventricular septum aneurysm, Pierre Robin syndrome (two forms), chromosomal deletion syndromes, orofacial clefting syndrome, Jeune syndrome with situs inversus, pulmonary valve disease, and a fucoglycan synthesis disorder. None has a recognizable mechanistic link, and none has supporting clinical trials. The five publications retrieved under the fucoglycan synthesis disorder prediction all concern polycythemia vera, the original indication, and do not support any repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for Laubry-Pezzi syndrome.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761166 | BESREMi (PharmaEssentia USA) | Injection | Not listed in the data compiled for this report (status: cancelled) |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy / immunomodulator (interferon class), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found in the data compiled for this report, and no knowledge-graph contraindications were recorded.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or literature for Laubry-Pezzi syndrome, no plausible mechanistic link to a structural cardiac defect, and the safety data are incomplete. The only US license is listed as cancelled.
To proceed, the following is needed:
- Package insert warnings and contraindications from the FDA (a blocking gap for safety screening)
- Detailed mechanism of action data (MOA) from DrugBank
- Any biological or preclinical evidence linking interferon signaling to the pathology of Laubry-Pezzi syndrome
- Clarification of the current US regulatory status of BESREMi (the BLA is listed as cancelled)
- Evaluation of whether the drug’s injectable route and its safety in the relevant (often pediatric) populations are compatible with the predicted indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.